新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 冠心病 » PNAS:多种生长因子参与血管调控 “生物搭桥”可治冠心病

PNAS:多种生长因子参与血管调控 “生物搭桥”可治冠心病

来源:生物谷 2007-08-13 09:11

    生物谷:促血管生长因子和促动脉生成因子联合应用,可促进心肌缺血组织血管的生成,从而改善心肌血液供应治疗冠心病。山东大学张运院士领导的心血管功能与重构研究重点实验室,与瑞典卡洛林斯卡研究院曹义海教授领导的血管再生实验室合作完成的这项研究成果,近日发表在国际权威期刊《美国科学院学报》上。  

    这项研究得到了国家基金委海外青年学者合作研究基金和科技部“973”项目支持。据课题组成员吕慧霞介绍,缺血性心肌病(即冠心病)主要是由于心肌的血氧供需失衡,病变的冠状动脉对心肌的灌注难以满足心肌的血氧需求而导致的。从理论上讲,最佳的治疗方法是改善冠脉的灌注。迄今为止,只有冠脉搭桥术和冠脉血管重建术等治疗方法能够做到这一点。如果能引入外源的生长因子(重组蛋白或基因),促进缺血组织血管的形成,以改善血液供应,对于缺血性心肌病来说,将是一种具有临床应用光明前景的治疗方法。这种被称为“生物搭桥”疗法的研究成为近年来医学研究的热点领域之一。但以往的研究集中于单一血管生长因子,大多只能生成结构和功能有缺陷的血管。  

    课题组研究发现,多种生长因子参与了血管生成的调控过程,促血管生长因子FGF-2在原始血管网络形成阶段起重要作用,促动脉生成因子PDGF-BB在促进血管的成熟和稳定方面起核心作用。这些因子必须在时间、空间和浓度上发挥协同作用,才能形成有功能的血管网络。动物试验结果表明,将这些生长因子制成缓释剂,包埋于梗死区周围的心肌缺血部位,缺血区心肌出现了显著增多的成熟而有功能的侧支血管网络,心肌局部血流量和收缩功能得到显著改善。(健康报)

原始出处:

Published online before print July 16, 2007, 10.1073/pnas.0704966104
PNAS | July 17, 2007 | vol. 104 | no. 29 | 12140-12145
BIOLOGICAL SCIENCES / MEDICAL SCIENCES


Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs

Huixia Lu*, Xinsheng Xu*, Mei Zhang*, Renhai Cao, Ebba Bråkenhielm, Changjiang Li*, Huili Lin*, Guihua Yao*, Huiwen Sun*, Lihang Qi*, Mengxiong Tang*, Hongyan Dai*, Yanen Zhang, Runyi Su, Yanwen Bi, Yun Zhang*,, and Yihai Cao,

*Key Laboratory of Cardiovascular Remodelling and Function Research, Chinese Ministry of Education and Public Health, Department of Cardiovascular Surgery, Qi Lu Hospital, Shandong University, Jinan 250012, Shandong Province, People's Republic of China; and Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden

Communicated by Tadamitsu Kishimoto, Osaka University, Osaka, Japan, May 25, 2007 (received for review April 2, 2007)

Establishment of functional and stable collaterals in the ischemic myocardium is crucial to restoring cardiac function after myocardial infarction. Here, we show that only dual delivery of a combination of angiogenic and arteriogenic factors to the ischemic myocardium could significantly reestablish stable collateral networks and improve myocardial perfusion and function. A combination of FGF-2 with PDGF-BB, two factors primarily targeting endothelial cells and vascular smooth muscle cells, remarkably promotes myocardial collateral growth and stabilizes the newly formed collateral networks, which significantly restore myocardial perfusion and function. Using various members of the PDGF family together with FGF-2 in an angiogenesis assay, we demonstrate that PDGFR- is mainly involved in angiogenic synergism, whereas PDGFR- mediates vessel stability signals. Our findings provide conceptual guidelines for the clinical development of proangiogenic/arteriogenic factors for the treatment of ischemic heart disease.

angiogenesis | growth factor | ischemia | myocardial infarction | neovascularization

相关报道:

冠心病的分布和危险因素

第一个冠心病致病基因被发现

冠心病市场:中药治疗前景广阔

典型的心绞痛症状 上腹痛多是冠心病先兆

我国调查显示抑郁症患者易得冠心病

胰岛素可改善有冠心病的糖尿病患者心肌灌注

γ-谷氨酰转移酶水平是冠心病风险的预测因子

冠心病的辩证论治

血管成形术前氯吡格雷降低冠心病患者死亡率

球囊切割术在冠心病介入治疗中的应用

多食谷类和水果纤维有助减少冠心病发作

同型半胱氨酸可能介导炎症和氧化应激诱导冠心病

蛋白质芯片为冠心病检测“加速”

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库